A randomized controlled study for minimally invasive posterior and anterolateral approaches in total hip replacement

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029515

Enrollment

Unknown

Registered

2020-02-03

Start date

2020-02-02

Completion date

Unknown

Last updated

2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage hip disease

Interventions

group A:Minimally invasive posterior transpiriformis approach

group B:Minimally invasive anterolateral approach

group C:Conventional posterolateral approach

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients need to undergoing THA for end-stage hip disease; Aged over 18 years; Signed informed consent from the patient or legal representative.

Exclusion criteria

Exclusion criteria: Previous surgery on affected hip; The patient has inflammatory arthritis; The patient has any type of infection; The subject has a known metal allergy.

Design outcomes

Primary

Measure	Time frame
length of incision;intraoperative blood loss;The first time to get out of bed after operation;hospital stays;blood loss;transfusion rate;inflammatory indicators;Muscle injury index;radiological examinations;	—

Secondary

Measure	Time frame
VAS pain score;Harris scale;SF-36 scale;	—

Countries

China

Contacts

Public ContactCong Xiao

xiaocong889900@163.com+86 13890459183

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026